BACKGROUND: To evaluate the safety, tolerability, pharmacokinetics, and dose-limiting toxicities of a single intravitreal (IVT) injection of PF-04523655, a 19-nucleotide, O-methyl stabilized, double-stranded small interfering ribonucleic acid targeting the RTP801 gene in patients with neovascular age-related macular degeneration (AMD). METHODS: Prospective, phase 1, clinical multicentre trial, enrolled 27 patients with neovascular AMD unresponsive to prior treatment and best corrected visual acuity (BCVA) ≤ 20/200 in the study eye in stratum 1: (dose-escalating, open-label: 50 to 3000 μg of PF-04523655) and 27 patients who had potential to benefit from therapy and BCVA of ≤ 20/100 and ≥ 20/800 in stratum 2 (parallel, masked study of 1000, 1500, 2250, and 3000 μg of PF-04523655). The primary outcome was safety and tolerability assessment as well as pharmacokinetic profiling following a single IVT injection of PF-04523655. RESULTS: Doses of PF-04523655 ≥ 400 μg were generally detectable in the plasma at 1, 4, and 24 h post-injection. And all doses were below the lowest level of quantification by day 14. A single IVT injection of 50 to 3000 μg of PF-045237655 was generally safe and well tolerated over 24 months. There were no dose-limiting toxicities. CONCLUSION: A single IVT injection of PF-0523655 ≤ 3000 μg seems safe and well tolerated in eyes with neovascular AMD.
RCT Entities:
BACKGROUND: To evaluate the safety, tolerability, pharmacokinetics, and dose-limiting toxicities of a single intravitreal (IVT) injection of PF-04523655, a 19-nucleotide, O-methyl stabilized, double-stranded small interfering ribonucleic acid targeting the RTP801 gene in patients with neovascular age-related macular degeneration (AMD). METHODS: Prospective, phase 1, clinical multicentre trial, enrolled 27 patients with neovascular AMD unresponsive to prior treatment and best corrected visual acuity (BCVA) ≤ 20/200 in the study eye in stratum 1: (dose-escalating, open-label: 50 to 3000 μg of PF-04523655) and 27 patients who had potential to benefit from therapy and BCVA of ≤ 20/100 and ≥ 20/800 in stratum 2 (parallel, masked study of 1000, 1500, 2250, and 3000 μg of PF-04523655). The primary outcome was safety and tolerability assessment as well as pharmacokinetic profiling following a single IVT injection of PF-04523655. RESULTS: Doses of PF-04523655 ≥ 400 μg were generally detectable in the plasma at 1, 4, and 24 h post-injection. And all doses were below the lowest level of quantification by day 14. A single IVT injection of 50 to 3000 μg of PF-045237655 was generally safe and well tolerated over 24 months. There were no dose-limiting toxicities. CONCLUSION: A single IVT injection of PF-0523655 ≤ 3000 μg seems safe and well tolerated in eyes with neovascular AMD.
Authors: Jeffrey S Heier; David Boyer; Quan Dong Nguyen; Dennis Marcus; Daniel B Roth; George Yancopoulos; Neil Stahl; Avner Ingerman; Robert Vitti; Alyson J Berliner; Ke Yang; David M Brown Journal: Ophthalmology Date: 2011-06 Impact factor: 12.079
Authors: Robert L Avery; Dante J Pieramici; Melvin D Rabena; Alessandro A Castellarin; Ma'an A Nasir; Matthew J Giust Journal: Ophthalmology Date: 2006-02-03 Impact factor: 12.079
Authors: Leif W Ellisen; Kate D Ramsayer; Cory M Johannessen; Annie Yang; Hideyuki Beppu; Karolina Minda; Jonathan D Oliner; Frank McKeon; Daniel A Haber Journal: Mol Cell Date: 2002-11 Impact factor: 17.970
Authors: Peter K Kaiser; R C Andrew Symons; Syed Mahmood Shah; Edward J Quinlan; Homayoun Tabandeh; Diana V Do; Gail Reisen; Jennifer A Lockridge; Brian Short; Roberto Guerciolini; Quan Dong Nguyen Journal: Am J Ophthalmol Date: 2010-07 Impact factor: 5.258
Authors: Gulnihal Ozcan; Bulent Ozpolat; Robert L Coleman; Anil K Sood; Gabriel Lopez-Berestein Journal: Adv Drug Deliv Rev Date: 2015-02-07 Impact factor: 15.470
Authors: J Wu; S Liu; J Yu; G Zhou; D Rao; C M Jay; P Kumar; R Sanchez; N Templeton; N Senzer; P Maples; J Nemunaitis; F C Brunicardi Journal: Cancer Gene Ther Date: 2014-01-24 Impact factor: 5.987
Authors: Lara Elis Alberici Delsin; Karina Bezerra Salomao; Julia Alejandra Pezuk; Maria Sol Brassesco Journal: J Cancer Res Clin Oncol Date: 2018-10-22 Impact factor: 4.553
Authors: Anne Louise Askou; Lars Aagaard; Corinne Kostic; Yvan Arsenijevic; Anne Kruse Hollensen; Toke Bek; Thomas Gryesten Jensen; Jacob Giehm Mikkelsen; Thomas Juhl Corydon Journal: Mol Ther Methods Clin Dev Date: 2015-01-28 Impact factor: 6.698